Screener
Veracyte VCYT G&A
G&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | 27,098 | 17,720 |
| Selling and marketing | 27,156 | 24,454 |
| General and administrative | 23,680 | 33,808 |
| Intangible asset amortization - operating expenses | 579 | 622 |
| Total operating expenses | 78,513 | 76,604 |
| Income from operations | 22,646 | 2,904 |
| Other income, net | 7,328 | 4,524 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's G&A?
- Veracyte (VCYT) reported G&A of $23.68M in Q1 2026.
- How has Veracyte's G&A changed year-over-year?
- Veracyte's G&A decreased by 30.0% year-over-year, from $33.81M to $23.68M.
- What is the long-term trend for Veracyte's G&A?
- Over 4 years (2021 to 2025), Veracyte's G&A has grown at a 2.2% compound annual growth rate (CAGR), from $101.35M to $110.78M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Veracyte's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude